PFE Nov 2024 30.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.6200

-0.1400

(-18.42%)

As of 03:59PM EDT. Market open.

Loading interactive chart...

Simply Wall St.
The past three years for Pfizer (NYSE:PFE) investors has not been profitable
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Investor's Business Daily
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
Business Wire
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK, October 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors.